A randomized clinical trial of mesalazine suppository

The usefulness and problems of central review of evaluations of colonic mucosal findings

Kiyonori Kobayashi, Fumihito Hirai, Makoto Naganuma, Kenji Watanabe, Takafumi Ando, Hiroshi Nakase, Katsuyoshi Matsuoka, Mamoru Watanabe

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The methods of evaluating endoscopic mucosal findings and the definition of mucosal healing in inflammatory bowel disease have not been standardized. Aim: To examine a third-party central review of colonic mucosal evaluations. Methods: A double-blind, placebo-controlled, parallel-group trial was performed for 4. weeks, which involved continuous administration of a 1-g mesalazine suppository to 129 patients with mild to moderate ulcerative colitis and active rectal inflammatory findings. Mucosal findings were evaluated by using a 4-grade score (0, 1, 2, 3). Reviews by attending physicians were considered the primary evaluations. Concurrently, a central review committee of 7 gastroenterologists served as the third party. Results: The endoscopic remission induction rate from the attending physicians' evaluations was 82.8% in the mesalazine suppository group and 31.1% in the placebo suppository group, whereas the respective rates from the central review committee were 90.6% and 59.0%. However, there was a difference of 27.9 percentage points between the remission induction rates of the placebo group found by the two groups of raters. Differences in the evaluations of mucosal finding scores were also found among the third-party reviewers. Conclusions: The evaluations of the attending physicians were consistent with those of the central review committee in showing the effectiveness of mesalazine suppository through the index of mucosal healing. However, differences were observed among the raters in their evaluations of mucosal finding scores. Therefore, standardizing evaluation criteria and improving review methods for mucosal findings would enable the more effective use of third-party central reviews in clinical drug trials.

Original languageEnglish
Pages (from-to)1444-1453
Number of pages10
JournalJournal of Crohn's and Colitis
Volume8
Issue number11
DOIs
Publication statusPublished - 2014

Fingerprint

Mesalamine
Suppositories
Randomized Controlled Trials
Advisory Committees
Remission Induction
Placebos
Physicians
Ulcerative Colitis
Inflammatory Bowel Diseases
Double-Blind Method
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Central review
  • Colonoscopy
  • Inter-rater reliability
  • Mucosal findings
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A randomized clinical trial of mesalazine suppository : The usefulness and problems of central review of evaluations of colonic mucosal findings. / Kobayashi, Kiyonori; Hirai, Fumihito; Naganuma, Makoto; Watanabe, Kenji; Ando, Takafumi; Nakase, Hiroshi; Matsuoka, Katsuyoshi; Watanabe, Mamoru.

In: Journal of Crohn's and Colitis, Vol. 8, No. 11, 2014, p. 1444-1453.

Research output: Contribution to journalArticle

Kobayashi, Kiyonori ; Hirai, Fumihito ; Naganuma, Makoto ; Watanabe, Kenji ; Ando, Takafumi ; Nakase, Hiroshi ; Matsuoka, Katsuyoshi ; Watanabe, Mamoru. / A randomized clinical trial of mesalazine suppository : The usefulness and problems of central review of evaluations of colonic mucosal findings. In: Journal of Crohn's and Colitis. 2014 ; Vol. 8, No. 11. pp. 1444-1453.
@article{b55a18b05d934ec68efb608311699b7e,
title = "A randomized clinical trial of mesalazine suppository: The usefulness and problems of central review of evaluations of colonic mucosal findings",
abstract = "Background: The methods of evaluating endoscopic mucosal findings and the definition of mucosal healing in inflammatory bowel disease have not been standardized. Aim: To examine a third-party central review of colonic mucosal evaluations. Methods: A double-blind, placebo-controlled, parallel-group trial was performed for 4. weeks, which involved continuous administration of a 1-g mesalazine suppository to 129 patients with mild to moderate ulcerative colitis and active rectal inflammatory findings. Mucosal findings were evaluated by using a 4-grade score (0, 1, 2, 3). Reviews by attending physicians were considered the primary evaluations. Concurrently, a central review committee of 7 gastroenterologists served as the third party. Results: The endoscopic remission induction rate from the attending physicians' evaluations was 82.8{\%} in the mesalazine suppository group and 31.1{\%} in the placebo suppository group, whereas the respective rates from the central review committee were 90.6{\%} and 59.0{\%}. However, there was a difference of 27.9 percentage points between the remission induction rates of the placebo group found by the two groups of raters. Differences in the evaluations of mucosal finding scores were also found among the third-party reviewers. Conclusions: The evaluations of the attending physicians were consistent with those of the central review committee in showing the effectiveness of mesalazine suppository through the index of mucosal healing. However, differences were observed among the raters in their evaluations of mucosal finding scores. Therefore, standardizing evaluation criteria and improving review methods for mucosal findings would enable the more effective use of third-party central reviews in clinical drug trials.",
keywords = "Central review, Colonoscopy, Inter-rater reliability, Mucosal findings, Ulcerative colitis",
author = "Kiyonori Kobayashi and Fumihito Hirai and Makoto Naganuma and Kenji Watanabe and Takafumi Ando and Hiroshi Nakase and Katsuyoshi Matsuoka and Mamoru Watanabe",
year = "2014",
doi = "10.1016/j.crohns.2014.05.005",
language = "English",
volume = "8",
pages = "1444--1453",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - A randomized clinical trial of mesalazine suppository

T2 - The usefulness and problems of central review of evaluations of colonic mucosal findings

AU - Kobayashi, Kiyonori

AU - Hirai, Fumihito

AU - Naganuma, Makoto

AU - Watanabe, Kenji

AU - Ando, Takafumi

AU - Nakase, Hiroshi

AU - Matsuoka, Katsuyoshi

AU - Watanabe, Mamoru

PY - 2014

Y1 - 2014

N2 - Background: The methods of evaluating endoscopic mucosal findings and the definition of mucosal healing in inflammatory bowel disease have not been standardized. Aim: To examine a third-party central review of colonic mucosal evaluations. Methods: A double-blind, placebo-controlled, parallel-group trial was performed for 4. weeks, which involved continuous administration of a 1-g mesalazine suppository to 129 patients with mild to moderate ulcerative colitis and active rectal inflammatory findings. Mucosal findings were evaluated by using a 4-grade score (0, 1, 2, 3). Reviews by attending physicians were considered the primary evaluations. Concurrently, a central review committee of 7 gastroenterologists served as the third party. Results: The endoscopic remission induction rate from the attending physicians' evaluations was 82.8% in the mesalazine suppository group and 31.1% in the placebo suppository group, whereas the respective rates from the central review committee were 90.6% and 59.0%. However, there was a difference of 27.9 percentage points between the remission induction rates of the placebo group found by the two groups of raters. Differences in the evaluations of mucosal finding scores were also found among the third-party reviewers. Conclusions: The evaluations of the attending physicians were consistent with those of the central review committee in showing the effectiveness of mesalazine suppository through the index of mucosal healing. However, differences were observed among the raters in their evaluations of mucosal finding scores. Therefore, standardizing evaluation criteria and improving review methods for mucosal findings would enable the more effective use of third-party central reviews in clinical drug trials.

AB - Background: The methods of evaluating endoscopic mucosal findings and the definition of mucosal healing in inflammatory bowel disease have not been standardized. Aim: To examine a third-party central review of colonic mucosal evaluations. Methods: A double-blind, placebo-controlled, parallel-group trial was performed for 4. weeks, which involved continuous administration of a 1-g mesalazine suppository to 129 patients with mild to moderate ulcerative colitis and active rectal inflammatory findings. Mucosal findings were evaluated by using a 4-grade score (0, 1, 2, 3). Reviews by attending physicians were considered the primary evaluations. Concurrently, a central review committee of 7 gastroenterologists served as the third party. Results: The endoscopic remission induction rate from the attending physicians' evaluations was 82.8% in the mesalazine suppository group and 31.1% in the placebo suppository group, whereas the respective rates from the central review committee were 90.6% and 59.0%. However, there was a difference of 27.9 percentage points between the remission induction rates of the placebo group found by the two groups of raters. Differences in the evaluations of mucosal finding scores were also found among the third-party reviewers. Conclusions: The evaluations of the attending physicians were consistent with those of the central review committee in showing the effectiveness of mesalazine suppository through the index of mucosal healing. However, differences were observed among the raters in their evaluations of mucosal finding scores. Therefore, standardizing evaluation criteria and improving review methods for mucosal findings would enable the more effective use of third-party central reviews in clinical drug trials.

KW - Central review

KW - Colonoscopy

KW - Inter-rater reliability

KW - Mucosal findings

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84927788306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927788306&partnerID=8YFLogxK

U2 - 10.1016/j.crohns.2014.05.005

DO - 10.1016/j.crohns.2014.05.005

M3 - Article

VL - 8

SP - 1444

EP - 1453

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 11

ER -